Voyager Therapeutics PE Ratio 2014-2020 | VYGR

Current and historical p/e ratio for Voyager Therapeutics (VYGR) from 2014 to 2020. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Voyager Therapeutics PE ratio as of May 26, 2020 is 0.00.
Voyager Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2020-05-27 12.30 0.00
2020-03-31 9.15 $-1.12 0.00
2019-12-31 13.95 $-1.27 0.00
2019-09-30 17.21 $-1.63 0.00
2019-06-30 27.22 $-1.85 0.00
2019-03-31 19.14 $-2.94 0.00
2018-12-31 9.40 $-2.76 0.00
2018-09-30 18.92 $-2.46 0.00
2018-06-30 19.54 $-2.72 0.00
2018-03-31 18.79 $-2.65 0.00
2017-12-31 16.60 $-2.67 0.00
2017-09-30 20.59 $-2.84 0.00
2017-06-30 8.96 $-2.30 0.00
2017-03-31 13.24 $-1.94 0.00
2016-12-31 12.74 $-1.58 0.00
2016-09-30 12.01 $-1.68 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.468B $0.104B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $13.456B 4.99
Dr Reddy's Laboratories (RDY) India $8.442B 20.21
Mylan (MYL) United States $8.343B 3.59
Bausch Health Cos (BHC) Canada $6.391B 4.26
BridgeBio Pharma (BBIO) United States $4.287B 0.00
ASPEN PHARMACR (APNHY) South Africa $3.574B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.304B 11.44
Amphastar Pharmaceuticals (AMPH) United States $0.854B 44.02
Homology Medicines (FIXX) United States $0.733B 0.00
Assembly Biosciences (ASMB) United States $0.659B 0.00
Personalis (PSNL) United States $0.395B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.341B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.283B 0.39
CymaBay Therapeutics (CBAY) United States $0.273B 0.00
Sol-Gel Technologies (SLGL) Israel $0.169B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.154B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.081B 0.00
Akorn (AKRX) United States $0.028B 1.50
China Pharma Holdings (CPHI) China $0.020B 0.00
Teligent (TLGT) United States $0.019B 0.00